The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.

Guidance around complete revascularization and intracoronary imaging is strengthened, and Impella gets a recommendation.

The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.

Clyde Yancy, Suzanne Baron, and Bruce Rutkin discuss ways to address the undertreatment of CVD in women at the patient, provider, structural, and societal levels.

Clyde Yancy talks to Sharonne Hayes and Robert Harrington about the barriers that have historically hindered diagnosing heart ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.